APOE及其他常见遗传变异对阿尔茨海默病和痴呆发病的影响:一项社区队列研究
该研究基于鹿特丹研究社区前瞻性队列,纳入12255名认知健康参与者,评估APOE及23个遗传变异对阿尔茨海默病和痴呆累积风险及发病年龄的影响。结果显示APOE与遗传风险评分显著改变风险,在APOE ε4纯合子中风险差异最大,极端风险组间阿尔茨海默病风险差58.6%,痴呆风险差70.3%,发病年龄差18-29年。
要点
- APOE与23个变异遗传风险评分对阿尔茨海默病和痴呆风险有显著交互作用(P=0.03和0.04)。
- APOE ε4纯合子中,高危及低危遗传风险评分三分位组85岁时阿尔茨海默病风险差27.0%,痴呆风险差37.2%。
- 风险极端组间85岁时阿尔茨海默病风险差58.6%,痴呆风险差70.3%,发病年龄差18-29年。
核心结论
- 常见变异共同改变阿尔茨海默病和痴呆的风险及发病年龄,尤其在APOE ε4携带者中。
- 这些发现凸显常见变异在确定阿尔茨海默病风险中的潜力。
研究设计与样本
- 基于鹿特丹研究的社区前瞻性队列,纳入12255名年龄>45岁的认知健康参与者,中位随访11.0年(IQR 4.9-15.9;133123人年)。
主要发现
- 随访期间1609人发生痴呆,其中1262人(78%)分类为阿尔茨海默病;3310人死于非痴呆原因。
- APOE基因型与遗传风险评分对阿尔茨海默病(P=0.03)和痴呆(P=0.04)存在显著交互作用。
- APOE ε4纯合子中,85岁时高危与低危遗传风险评分三分位组风险差:阿尔茨海默病27.0%(P=8.5×10^-3),痴呆37.2%(P=2.2×10^-4),发病年龄差7-10年。
- 风险极端组(低危遗传风险评分三分位组中APOE ε2纯合子或ε2/ε3杂合子 vs 高危三分位组中APOE ε4纯合子)85岁时风险差:阿尔茨海默病58.6%(4.1% vs 62.7%;P=6.2×10^-13),痴呆70.3%(7.2% vs 77.5%;P=3.0×10^-23),发病年龄差阿尔茨海默病18-29年、痴呆18-23年。
- 考虑父母痴呆史后风险差更明显(风险差83.8%;P=1.1×10^-20)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alzheimer's disease is one of the most heritable diseases in elderly people and the most common type of dementia. In addition to the major genetic determinant of Alzheimer's disease, the APOE gene, 23 genetic variants have been associated with the disease. We assessed the effects of these variants and APOE on cumulative risk and age at onset of Alzheimer's disease and all-cause dementia. METHODS: We studied incident dementia in cognitively healthy participants (aged >45 years) from the community-based Rotterdam Study, an ongoing prospective cohort study based in Rotterdam, the Netherlands, focusing on neurological, cardiovascular, endocrine, and ophthalmological disorders, and other diseases in elderly people. The Rotterdam Study comprises participants in three baseline cohorts (initiated in 1990, 2000, and 2006), who are re-invited to the research centre every 3-4 years, and continuously monitored by records from general practitioners and medical specialists. Cumulative incidence curves up to age 100 years were calculated for Alzheimer's disease and dementia, taking into account mortality as a competing event. These risk curves were stratified by APOE genotypes, tertiles of a weighted genetic risk score (GRS) of 23 Alzheimer's disease-associated genetic variants, and parental history of dementia. FINDINGS: 12 255 of 14 926 participants (58·5% women) from the Rotterdam Study were included in this study. During a median follow-up of 11·0 years (IQR 4·9-15·9; 133 123 person years), 1609 participants developed dementia, of whom 1262 (78%) were classified as having Alzheimer's disease; 3310 people died of causes other than dementia. Both APOE and the GRS significantly modified the risks of Alzheimer's disease and dementia. There was evidence for a significant interaction between APOE genotypes and the GRS for the association with Alzheimer's disease (p=0·03) and dementia (p=0·04); the risk for carriers homozygous for APOE ε4 was modified most by the GRS. In carriers homozygous for APOE ε4, the difference between the high-risk tertile and the low-risk tertile by age 85 years was 27·0% for Alzheimer's disease (p=8·5 × 10-3) and 37·2% for dementia (p=2·2 × 10-4), which translates to a 7-10 year difference in age at onset. Comparing the risk extremes, which were carriers homozygous for APOE ε2 or heterozygous with one copy each of the ε2 and ε3 alleles in the low-risk tertile of the GRS versus carriers homozygous for APOE ε4 in the high-risk tertile of the GRS, the difference in risk by age 85 years was 58·6% (4·1% vs 62·7%; p=6·2 × 10-13) for Alzheimer's disease, and 70·3% (7·2% vs 77·5%; p=3·0 × 10-23) for dementia. These risk differences translate into an 18-29 years difference in age at onset for Alzheimer's disease and an 18-23 year difference in age at onset dementia. This difference becomes more pronounced when parental history of dementia is considered (difference in risk 83·8%; p=1·1 × 10-20). INTERPRETATION: Common variants with small individual effects jointly modify the risk and age at onset of Alzheimer's disease and dementia, particularly in APOE ε4 carriers. These findings highlight the potential of common variants in determining Alzheimer's disease risk. FUNDING: None.
引用
- van der Lee SJ, Wolters FJ, Ikram MK, et al. The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study. Lancet Neurol. 2018. PMID: 29555425. doi:10.1016/S1474-4422(18)30053-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。